Amoy Diagnostics Co., Ltd. (SHE:300685)

Market Cap	8.18B
Revenue (ttm)	1.15B
Net Income (ttm)	281.14M
Shares Out	393.06M
EPS (ttm)	0.71
PE Ratio	29.35
Forward PE	24.96
Dividend	0.15 (0.72%)
Ex-Dividend Date	May 30, 2024

Volume	3,073,215
Average Volume	6,933,086
Open	20.85
Previous Close	20.72
Day's Range	20.84 - 21.16
52-Week Range	17.20 - 28.79
Beta	0.91
RSI	42.48
Earnings Date	Apr 22, 2025

About Amoy Diagnostics

Amoy Diagnostics Co., Ltd. engages in the development and commercialization of diagnostics product for oncology in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers, and advances targeted treatment research in ovarian cancer; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a CGP assay; AmoyDx BRCA Pro panel, covers various protein coding regions, intron/exon boundaries, sele...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2008
• Employees: 1,119
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300685

Financial Performance

In 2024, Amoy Diagnostics's revenue was 1.11 billion, an increase of 6.27% compared to the previous year's 1.04 billion. Earnings were 254.86 million, a decrease of -2.53%.